The past year has seen the rapid global spread of SARS-CoV-2—the virus responsible for the ongoing COVID-19 pandemic. While non-pharmaceutical interventions have been the mainstay of epidemic control to date, vaccination is likely to constitute the definitive, long-term defence strategy against SARS-CoV-2 morbidity, mortality, and transmission, offering the best hope of a return to normal life.

The urgent need for effective vaccines has prompted vaccine developers to pivot towards COVID-19, resulting in rapid growth of preclinical candidates (appendix) and an accelerated vaccine development pipeline.1SARS-CoV-2 vaccines in development.